HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

CIR News In Brief: No Conclusion Reached On PHMB; Endocrine Activity Guidance; More

This article was originally published in The Rose Sheet

Executive Summary

At its Sept. 11-12 meeting in Washington, the Cosmetic Ingredient Review Expert Panel finalized reports for various protein and peptide ingredient families, among others, and advanced six tentative reports. The panel issued a tentative insufficient data conclusion for broad-spectrum preservative polyaminopropyl biguanide, with concerns about sensitization continuing to weigh on the group.

You may also be interested in...



NGO Women’s Voices Will Keep After CIR Following 2019 Progress – Science Director Alex Scranton

Alexandra Scranton, director of science and research at Women’s Voices for the Earth, highlights achievements in 2019 in the group’s Cosmetic Ingredient Review-focused activities, including parameters the Expert Panel placed on preservative use of parabens, PHMB and MCI/MI.

CIR: Industry Working On Producing Preservative PHMB Sensitization Data

The Cosmetic Ingredient Review Expert Panel issued final safety conclusions for five ingredients at its Dec. 4-5 meeting, as well as six tentative reports and two insufficient data announcements. According to a post-meeting recap, industry is working to complete a sensitization study for preservative polyaminopropyl biguanide at the panel's request.

Cosmetic Ingredient Review Report Status

Chart: Data compiled by the Rose Sheet from information in CIR reports following the Expert Panel's Sept. 11-12 meeting.

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

RS121207

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel